Selected highlights from the European Academy of Neurology annual meeting, Budapest, Hungary, July 1-4, 2023.
Few patients achieve an optimal response with platform therapies
Fluid biomarkers predict early disease activity
When does PIRA start?
MOG antibodies uncommon
Clinical tip of the day Read More
The following is a quick summary of interesting reports in the literature for June 2023.
COVID-19
CNS infection
Alzheimer’s disease
Biomarkers
Headache
Multiple sclerosis
Neurodegenerative disorders
Neuromyelitis optica
Stroke Read More
CMSC 2023
An emerging therapeutic target of interest is CD40 and its ligand (CD40L), which initially drew attention for their role in activating B cells and macrophages in response to infection (reviewed in Ots et al. Int J Mol Sci 2022;23:4115). Subsequent investigations implicated abnormal CD40 expression in a number of neurological disorders, including multiple sclerosis. Read More
Includes data on early use of high-efficacy DMTs, risks of undertreatment of MS, safety issues and de-risking anti-CD20 therapy during long-term use.
16 slides
The Consortium of MS Clinics (CMSC) annual meeting concluded on June 3, 2023. The following are some selected highlights from the symposium. Read More